Endurance Wealth Management Inc. trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 2.4% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 151,784 shares of the biopharmaceutical company’s stock after selling 3,775 shares during the period. Endurance Wealth Management Inc.’s holdings in Pfizer were worth $5,454,000 as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in PFE. Nuveen Asset Management LLC increased its holdings in shares of Pfizer by 2,240.5% during the 2nd quarter. Nuveen Asset Management LLC now owns 36,086,254 shares of the biopharmaceutical company’s stock worth $1,563,256,000 after buying an additional 34,544,423 shares during the last quarter. Natixis acquired a new stake in Pfizer in the 2nd quarter valued at $258,466,000. Invesco Ltd. increased its holdings in Pfizer by 14.6% in the 2nd quarter. Invesco Ltd. now owns 21,118,606 shares of the biopharmaceutical company’s stock valued at $914,857,000 after purchasing an additional 2,693,349 shares in the last quarter. DNB Asset Management AS increased its holdings in Pfizer by 241.0% in the 3rd quarter. DNB Asset Management AS now owns 3,734,044 shares of the biopharmaceutical company’s stock valued at $134,164,000 after purchasing an additional 2,638,873 shares in the last quarter. Finally, Thoroughbred Financial Services LLC increased its holdings in Pfizer by 4,297.8% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 2,656,678 shares of the biopharmaceutical company’s stock valued at $265,668,000 after purchasing an additional 2,596,269 shares in the last quarter. Institutional investors and hedge funds own 71.52% of the company’s stock.
NYSE:PFE traded up $0.14 on Friday, reaching $37.05. The stock had a trading volume of 24,924,227 shares, compared to its average volume of 23,366,957. The company has a current ratio of 1.47, a quick ratio of 1.21 and a debt-to-equity ratio of 0.60. The company has a 50-day moving average of $36.62 and a 200 day moving average of $39.26. The stock has a market cap of $207.30 billion, a P/E ratio of 12.35, a price-to-earnings-growth ratio of 2.11 and a beta of 0.67. Pfizer Inc. has a 12-month low of $33.97 and a 12-month high of $46.47.
The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a dividend of $0.36 per share. The ex-dividend date is Thursday, November 7th. This represents a $1.44 annualized dividend and a dividend yield of 3.89%. Pfizer’s payout ratio is 48.00%.
In related news, Director Scott Gottlieb purchased 3,000 shares of Pfizer stock in a transaction dated Friday, August 23rd. The shares were acquired at an average price of $34.72 per share, with a total value of $104,160.00. Following the completion of the transaction, the director now owns 3,000 shares of the company’s stock, valued at approximately $104,160. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Pfizer Inc purchased 50,000 shares of Pfizer stock in a transaction dated Tuesday, September 17th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $900,000.00. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.
Several analysts recently issued reports on the company. Bank of America assumed coverage on Pfizer in a report on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 price target for the company. UBS Group reiterated a “neutral” rating and issued a $43.00 price target on shares of Pfizer in a report on Monday, August 5th. ValuEngine upgraded Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Pfizer in a report on Tuesday, October 29th. Finally, DZ Bank upgraded Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price target for the company in a report on Wednesday, August 28th. Nine equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Pfizer presently has a consensus rating of “Hold” and a consensus target price of $44.02.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Article: Sell-Side Analysts
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.